Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma.
OBJECTIVE
This study is designed to review a carcinoembryonic antigen (CEA)-driven postoperative protocol designed to identify patients suitable for curative reresection when recurrent colorectal cancer is identified.


METHODS
A total of 285 patients who were operated on for colon or rectal carcinoma between 1981 and 1985 were evaluated (with CEA levels) every two months for the first two years, every three months for the third year, every six months for years 4 and 5, and annually thereafter. CEA levels above 5 microg were considered abnormal and were evaluated with diagnostic imaging and/or endoscopy.


RESULTS
Follow-up was available for 280 patients (98.2 percent). Distribution of patients by Astler-Coller was: A, 14 percent; B1, 20 percent; B2, 39 percent; C1, 5 percent; C2, 21 percent. There were 62 of 280 patients (22 percent) who developed elevated CEA levels, with 44 patients who demonstrated clinical or radiographic evidence of recurrence. Eleven patients were selected for surgery with curative intent (4 hepatic resections, 1 pulmonary wedge resection, 2 abdominoperineal resections, 2 segmental bowel resections, and 2 cranial metastasectomies). Three of 11 patients (27 percent) benefited and have disease-free survivals greater than 60 months. Of the 223 patients without elevated CEA, 22 (9.9 percent) had recurrent cancer without any survivors. Overall, 3 of 285 patients (1.1 percent) were cured as a result of CEA follow-up.


CONCLUSIONS
CEA-driven surgery is useful in selected patients and can produce long-term survivors.
Lucha
P A
PA
Naval Medical Center, Division of Colon and Rectal Surgery, Portsmouth, Virginia, USA.
Rosen
L
L
Olenwine
J A
JA
Reed
J F
JF
Riether
R D
RD
Stasik
J J
JJ
Khubchandani
I T
IT
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000401:mortality / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D011182:Postoperative Care; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013997:Time Factors
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen